By staff writers

January 22, 2009 -- Ultrasound contrast developer Acusphere said that its Imagify echocardiography contrast agent was found to be well tolerated in newly published research, along with offering comparable diagnostic performance to nuclear imaging.

The phase III clinical trial data were published in the January 2009 issue of the European Journal of Echocardiography, according to the Watertown, MA-based vendor.

Acusphere executive resigns, January 8, 2009

FDA panel rejects Acusphere contrast agent, December 11, 2008

FDA 'concerned' over Acusphere agent, December 9, 2008

Bernstein leaves Acusphere, November 18, 2008

Acusphere's Imagify to get FDA review, October 13, 2008

Copyright © 2009


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking